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Background: Patients with CF suffer repeated pulmonary exacerbations with clinical
deterioration. Antibiotics are often commenced empirically and later reﬁned upon
results of antibiotic susceptibility testing of isolated organism(s).
Aim: To audit the bacteriology, sampling and management guidelines for pulmonary
exacerbations in CF.
Method: We completed a retrospective case-note audit of patients attending the
Children and Young Persons CF Unit, Nottingham UK (Jan 2005–Nov 2010). The respi-
ratory sampling, antibiotic susceptibility testing and antibiotic prescribing guidance was
audited. Episodes were classiﬁed according to the concordance between the antibiotics
prescribed, antibiotic susceptibility proﬁles of isolated organisms and clinical outcome.
First episodes for each patient were taken as the unit of analysis for the outcome
analysis; differences between groups were tested using ANOVA.
Results: In total 257 exacerbations were identiﬁed, of which 91.1% had respiratory
sampling documented. Antibiotic susceptibility testing was undertaken on 93% of
episodes that isolated P. aeruginosa; no antibiotic prescriptions were changed due to the
results. Outcomes did not differ between groups classiﬁed by antibiotic susceptibility,
although the audit did not have sufﬁcient power to detect a difference if such a difference
were present.
Outcome for ﬁrst exacerbation for each patient
Mean (sd) Bacteria sensitive
to both antibiotics










FEV1 % predicted n = 19 3.00 (9.71) 15.80 (17.78) 5.25 (7.59) 0.18
BMI change (kg/m2)
n = 21
0.25 (0.34) 0.25 (0.43) 0.40 (0.31) 0.78
Time to next exacerbation
(months) n = 19
5.25 (3.73) 6.14 (3.08) 3.00 (0.82) 0.22
Conclusion: Management follows published guidance. Outcomes appear to be inde-
pendent of antibiotic susceptibility-directed antibiotic selection.
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Bacteria belonging to the Burkholderia cepacia complex (Bcc) are signiﬁcant
pathogens in Cystic Fibrosis (CF) patients and are resistant to a plethora of
antibiotics. In this context microorganisms from Antarctica are interesting since
they produce antimicrobial compounds inhibiting the growth of other bacteria.
This is particularly true for bacteria isolated from Antarctic sponges. The aim
of this work was to check bacterial communities isolated from three Antarctic
sponges for their ability to produce new natural drugs that could be exploited
in the control of infections in CF patients by Bcc bacteria. Hence, 132 bacterial
strains afﬁliated to different genera (e.g., Pseudoalteromonas, Arthrobacter and
Psychrobacter) were tested (through the cross-streaking method) for their ability to
inhibit the growth of 23 Bcc strains and some other human pathogens. Most of these
bacteria completely inhibited the growth only of all the Bcc strains, suggesting a
highly speciﬁc activity toward Bcc strains. The PCR ampliﬁcation of genes coding
for multienzyme complexes (PKS or NRPS) from the Antarctic bacteria revealed
that only in few cases an amplicon of the expected size was obtained. Besides,
the antimicrobial compounds are small volatile organic compounds (VOCs), and
are constitutively produced via an unknown pathway. These data highlight the
potentiality of Antarctic bacteria as novel sources of antibacterial substances to
face Bcc infections in CF patients.
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There is growing concern about the relevance of in vitro antimicrobial susceptibility
tests when applied to isolates of P. aeruginosa from CF patients. During chronic lung
infections in CF, P. aeruginosa populations exist in bioﬁlms and a microaerophilic
environment, whereas current tests use planktonic growth and aerobic conditions.
In artiﬁcial sputum medium (ASM), P. aeruginosa growth mimics growth during
CF infections, with the formation of bioﬁlm structures and population divergence.
The aim of this study was to develop an assay to study antimicrobial susceptibility
of P. aeruginosa based on growth in ASM, and applicable to microaerophilic as
well as aerobic conditions.
An ASM assay was developed in a 24-well format, using 3 days growth of
P. aeruginosa prior to incubation with antimicrobial agents at different concen-
trations for 24 h. After bioﬁlm disruption, cell viability was measured following
staining with resazurin. The assay was applied to 16 P. aeruginosa under aerobic
and microaerophilic conditions, and the MICs for tobramycin were compared with
the results of susceptibility tests using standard broth growth. Whilst there was
some evidence for increased MIC for tobramycin for isolates grown in ASM when
compared to their planktonic counterparts, the biggest differences were found with
bacteria grown in microaerophilic conditions, which showed a much increased
resistance towards tobramycin in the ASM system compared to aerobic cultures.
We acknowledge Novartis Pharmaceuticals UK Ltd (unrestricted educational grant),
Wellcome Trust and the NIHR.
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Introduction and Aims: Aanaerobic bacteria have been detected in large numbers
from the sputum of patients with CF and non-CF bronchiectasis. This study aimed
to compare the susceptibility of these bacteria to a range of antibiotics used in the
treatment of anaerobic infection.
Methods: The susceptibility (Minimum inhibitory concentration, MIC) of 78 anaer-
obic isolates (46 CF and 32 non-CF), including isolates from the genera Prevotella,
Veillonella and Actinomyces, to 4 antibiotics (ampicillin, clindamycin, meropenem
and metronidazole) was determined by E-test. Isolates were classiﬁed as susceptible,
intermediate or resistant according to Clinical and Laboratory Standards Institute
guidelines.
Results: Eleven CF isolates (23.9%) were susceptible to all four antibiotics with
no isolates resistant to all 4 agents tested. Resistance to meropenem occurred in
2.1% of CF isolates with higher levels of resistance to ampicillin (21.0%), clin-
damycin (21.7%) and metronidazole (43.5%). In contrast, only one non-CF isolate
(3.1%) was susceptible to all four antibiotics with none resistant to all 4 antibiotics.
Levels of resistance amongst non-CF isolates were similar for meropenem (0%) and
clindamycin (12.5%) but higher for ampicillin (43.8%) and metronidazole (68.8%).
Conclusion: There were high levels of resistance amongst isolates from both CF
and non-CF bronchiectasis patients to metronidazole. Therefore, antibiotics such as
metronidazole with putative antimicrobial activity against anaerobic bacteria may
not be effective in the treatment of pulmonary infection caused by anaerobes.
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